PHOTODYNAMIC THERAPY IN THE MANAGEMENT OF PERIORBITAL SKIN CANCER

Jerjes W, Hamdoon Z, Sultan A, Hopper C

Periorbital skin cancers

- High cosmetic sensitivity
- Function and cosmesis of the area
- Simple dysfunctional problems can lead to facial deformity
- Inadequate treatment would necessitate further resection

Periorbital skin tumours

- Benign or malignant
- BCC and SCC most common ones
- Early diagnosis and intervention is essential
- The gold standard intervention surgery
- Other interventions: radiotherapy,
 chemotherapy, Mohs micrographic surgery,
 cryptherapy, topical interventions and
 photodynamic therapy

Prospective study

- 18 patients with periorbital lesions
- These BCCs and thin SCCs were treated with surface illumination mTHPC-PDT

- Comparisons were made with the clinicopathological parameters, anatomical location, rate of recurrence and overall outcome.
- Follow-up mean of 3.2 years

Treatment parameters

- For the BCC lesions, IV 0.05mg/kg mTHPC
- DLI of 48hrs
- Micro-infiltration safety margin: 2mm

- For cutaneous SCC lesions, IV 0.1mg/kg mTHPC
- DLI of 96hrs
- Micro-infiltration safety margin: 5mm.

Age at diagnosis Minimum Maximum Mean ±SD	41 72 55.4±12.3	Results	
Gender		Other risk factors	
Male	14 (77.8)	Chronic sun bathing	12 (66.7)
Female	4 (22.2)	Chronic non-healing wounds	1 (5.6)
		Genetic syndromes	0 (0.0)
Race		HPV infection	0 (0.0)
Caucasian	16 (88.9)	Ionizing radiation	0 (0.0)
Indian	2 (11.1)	Environmental carcinogens	0 (0.0)
		Artificial UV radiation	0 (0.0)
Smoking status			
Life long smoker <20	1 (5.6)	Clinical description	
Life long smoker >20	6 (33.3)	Macules	3 (16.7)
Ex-smoker <20	2 (11.1)	Papules	9 (50.0)
Ex-smoker >20	4 (22.2)	Ulcers	6 (33.3)
Non-smoker	5 (27.8)		
		Presenting complaint/concern	
Drinking status		Pain	4 (22.2)
Life long drinker <21	1 (5.6)	Itchiness	8 (44.4)
Life long drinker >21	4 (22.2)	Bleeding	3 (16.7)
Ex-drinker <21	3 (16.7)	Cosmetic	12 (66.7)
Ex-drinker >21	3 (16.7)	Fear of malignancy	16 (88.9)
Non-drinker	7 (38.8)		

Results

Primary site (18 lesions)

Supraorbital area	1 (5.6)
Infraorbital area	4 (22.2)
Medial canthal area	6 (33.3)
Lateral canthal area	7 (39.9)

Relevant Medical history

Hx of actinic keratosis	7 (38.9)
Hx of BCC	6 (33.3)
Hx of skin SCC	3 (16.7)
Immunodeficiency	1 (5.6)
Hx of other SCC	1 (5.6)

Diagnosis

Thin SCC	4 (22.2)
BCC	14 (77.8)



1st round of PDT for SCC

1 Tourid of FB1 for SCC	
Complete response	4 (100.0)
Partial response	0 (0.0)
Stable disease	0 (0.0)
Progressive locoregional disease	0 (0.0)
Progressive metastatic disease	0 (0.0)
1 st round of PDT for BCC	
Complete response	12 (85.8)
Partial response	1 (7.1)
Stable disease	1 (7.1)
Progressive disease	0 (0.0)
2 nd round of PDT for BCC	
Complete response	2 (100.0)
Partial response	0 (0.0)
Stable disease	0 (0.0)
Progressive disease	0 (0.0)
Recurrence	0 (0.0)

Results

Follow-up

Minimum31Maximum58Mean ±SD (months)38±6.2

Final cosmetic outcome

Excellent (9-10)	15 (83.3)
Good (VAS 7-8)	2 (11.1)
Fair (VAS 4-6)	1 (5.6)
Poor (<4)	0 (0.0)



Conclusion

 PDT is a successful modality in the management of these pathologies with an excellent cosmetic outcome.

 PDT should be considered as an alternative therapeutic strategy for the adequate and cosmetic treatment of lesions in these areas.

Thank you

Questions?